Traws Pharma, Inc.
Traws Pharma, Inc. (TRAW) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · TRAW · as of Jun 8, 2026
Key Statistics
Explore Traws Pharma, Inc. Data
traw stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
The TRAW analyst consensus is Buy, based on ratings from 1 Wall Street analysts over the past 3 months. The average 12-month price target is $8.00, representing +477.62% upside from the current price of $1.39.
Competitors & Peers
traw competitorsTRAW
BOLT
BRTX
CING
COCP
DWTXStock Performance
Full HistoryAbout Traws Pharma, Inc.
Traws Pharma, Inc. a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections a…
what is traws pharma, inc. · traw stock overview · traws pharma, inc. company profile · who is traws pharma, inc. ceo · traw NASDAQ · traws pharma, inc. headquarters · traws pharma, inc. business segments
About Stock Overview & Key Data
Traws Pharma, Inc. (TRAW) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 25, 2013. As of the latest trading session, TRAW stock price is $1.39, with a market capitalization of $12.5M. The stock has returned -17.47% over the past 12 months and +21.24% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Traws Pharma, Inc. stock is Buy, with an average 12-month price target of $8.00. In fiscal year 2025, Traws Pharma, Inc. reported revenue of $2.8M and net income of $9.2M. For detailed data — including Traws Pharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Traws Pharma, Inc. (TRAW) stock price is $1.39. The stock is traded on NASDAQ under the ticker symbol TRAW. The 52-week range is $1.00 – $3.27.